Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective boosted by Canaccord Genuity Group from $875.00 to $922.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently weighed in on REGN. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th. Truist Financial boosted their price target on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Raymond James Financial upped their price target on shares of Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the company an “outperform” rating in a research report on Friday, July 31st. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, The Goldman Sachs Group raised their price objective on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $850.83.
Check Out Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Price Performance
Shares of REGN opened at $927.89 on Wednesday. The firm has a fifty day simple moving average of $793.30 and a two-hundred day simple moving average of $738.05. The firm has a market cap of $95.54 billion, a PE ratio of 21.02, a P/E/G ratio of 1.38 and a beta of 0.16. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals has a 1-year low of $591.52 and a 1-year high of $935.35.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same period last year, the business posted $11.83 EPS. The company’s revenue for the quarter was up 36.3% on a year-over-year basis. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.
Insider Buying and Selling
In other news, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,093 shares of company stock worth $6,506,845. Company insiders own 6.97% of the company’s stock.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Covestor Ltd increased its stake in shares of Regeneron Pharmaceuticals by 31.5% in the third quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 41 shares in the last quarter. Compass Financial Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4,526.2% during the 3rd quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after buying an additional 2,942 shares in the last quarter. Pzena Investment Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $310,000. Rakuten Investment Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 8.6% during the 3rd quarter. Rakuten Investment Management Inc. now owns 26,693 shares of the biopharmaceutical company’s stock valued at $20,033,000 after buying an additional 2,113 shares in the last quarter. Finally, Provenance Wealth Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 208.0% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 619 shares of the biopharmaceutical company’s stock worth $469,000 after buying an additional 418 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.
Trending Headlines about Regeneron Pharmaceuticals
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
- Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
- Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
- Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
- Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.
Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
